New drug aims to wipe out hidden leukemia cells

NCT ID NCT07566364

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 8 times

Summary

This phase 2 trial tests the drug mosunetuzumab in 30 people with chronic lymphocytic leukemia (CLL) who still have detectable cancer cells after at least six months of standard therapy. The goal is to see if the drug can clear those remaining cells and improve outcomes. Participants must have had at least two prior treatments and meet specific high-risk criteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mosunetuzumab (Lunsumio)
What this could lead to: If successful, this could offer a new option to eliminate remaining leukemia cells in patients who have already received other treatments.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the drug could occur, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia lymphoid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

UT MD Anderson
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.